Section of Neurology, Hospital A. Marcide, Ferrol, Spain.
Neurology. 2012 Mar 6;78(10):696-701. doi: 10.1212/WNL.0b013e318248e520. Epub 2012 Feb 8.
To assess the role of DaTSCAN in the diagnosis of Parkinson disease (PD).
Using the sensitivity and specificity values obtained in the 2 studies that recently led the US Food and Drug Administration to approve the use of DaTSCAN for the diagnosis of PD, calculations were carried out to estimate the accuracy of the clinical diagnosis taking DaTSCAN findings as the standard of truth.
In early PD, a clinical diagnosis of "possible" or "probable" PD has a sensitivity of 98% and a specificity of 67%. The specificity increases to 94% once the clinical diagnosis becomes established. The overall accuracy of the clinical diagnosis is 84% in early PD and 98% at later stages. The clinical diagnostic accuracy is mathematically identical to the diagnostic accuracy of DaTSCAN imaging.
In the absence of neuropathologic validation, the overall accuracy of a clinical diagnosis of PD is very high and mathematically identical to the accuracy of DaTSCAN imaging, which calls into question the use of radiotracer neuroimaging as a diagnostic tool in clinical practice.
评估 DaTSCAN 在帕金森病（PD）诊断中的作用。
使用最近两项研究的灵敏度和特异性值，这些研究促使美国食品和药物管理局批准将 DaTSCAN 用于 PD 的诊断，计算得出以 DaTSCAN 检查结果作为金标准的临床诊断的准确性。
在早期 PD 中，“可能”或“很可能” PD 的临床诊断具有 98%的灵敏度和 67%的特异性。一旦临床诊断明确，特异性增加至 94%。在早期 PD 中，临床诊断的总体准确率为 84%，在晚期则为 98%。临床诊断的准确性在数学上与 DaTSCAN 成像的诊断准确性相同。
在缺乏神经病理学验证的情况下，PD 的临床诊断总体准确率非常高，且在数学上与 DaTSCAN 成像的准确性相同，这使得放射性示踪剂神经影像学在临床实践中作为诊断工具的使用受到质疑。
